Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia
- PMID: 19000557
- DOI: 10.5414/cpp46584
Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia
Abstract
Objective: Oral mucositis is a major toxicity in the high-dose methotrexate (HD-MTX) treatment for children with acute lymphoblastic leukemia (ALL). The first aim of this study was to evaluate the relationship between the MTX serum concentration and occurrence of oral mucositis in pediatric ALL patients. The second aim was to clarify the relationship between MTX exposure and epidermal keratinocyte cell injury using an in vitro study.
Methods: 49 patients were treated according to the Japan Association of Childhood Leukemia Study (JACLS) ALL-HR02 protocol. This protocol involves HD-MTX treatment (3 g/m2 for 24-h i.v. infusion). The MTX serum concentrations were measured by a fluorescence polarization immunoassay. The relationship between oral mucositis and MTX serum concentrations 48 and 72 h after administration was determined. The cell toxicity of MTX for human epidermal keratinocytes was analyzed by using a cell viability assay (WST-1 assay). In addition, pharmacokinetic evaluation for clearance, AUC extrapolated from 48 h to infinity (AUC48h-inf) and elimination half-life (t1/2b) were done using the 1-compartmental models.
Results: Oral mucositis occurred in 24 patients (49.0%), in whom 20 patients (83.3% in oral mucositis group) showed WHO severity Grade 1 or 2. Only 4 patients (16.7% in oral mucositis group) showed Grade 3 severity. 22 patients (44.9%) had oral mucositis in the group with a concentration under 10-6 M 48 h after MTX administration. There was no significant deference among the cell viabilities in the concentrations of 10-6 M, 10-5 M and 10-4 M 48 h after the MTX exposure. However, the cell viability obtained 24 h after the MTX exposure was significantly different from the respective cell viability 48, 72 and 96 h after the MTX exposure. In the group with oral mucositis, the clearance decreased significantly (p = 0.042), and the t1/2b (p = 0.025) and AUC48h- yen (p = 0.025) increased significantly compared with the non-symptom group.
Conclusions: It seems that there is no significant relationship between the serum MTX concentration and oral mucositis. This in vitro study has demonstrated that the cell injury was related to the duration of MTX exposure rather than a high MTX concentration.
Similar articles
-
Global methylation in relation to methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.PLoS One. 2018 Jul 9;13(7):e0199574. doi: 10.1371/journal.pone.0199574. eCollection 2018. PLoS One. 2018. PMID: 29985926 Free PMC article.
-
High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.Pediatr Blood Cancer. 2004 Jul;43(1):17-22. doi: 10.1002/pbc.20032. Pediatr Blood Cancer. 2004. PMID: 15170885 Clinical Trial.
-
Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate.Pediatr Hematol Oncol. 1996 Jul-Aug;13(4):359-67. doi: 10.3109/08880019609030842. Pediatr Hematol Oncol. 1996. PMID: 8837142
-
The effect of leucovorin rescue therapy on methotrexate-induced oral mucositis in the treatment of paediatric ALL: A systematic review.Crit Rev Oncol Hematol. 2019 Oct;142:1-8. doi: 10.1016/j.critrevonc.2019.07.003. Epub 2019 Jul 9. Crit Rev Oncol Hematol. 2019. PMID: 31323533
-
What can clinicians learn from therapeutic studies about the treatment of acute oral methotrexate poisoning?Clin Toxicol (Phila). 2017 Feb;55(2):88-96. doi: 10.1080/15563650.2016.1271126. Clin Toxicol (Phila). 2017. PMID: 28084171 Review.
Cited by
-
Acute Myeloid Leukaemia and Acute Lymphoblastic Leukaemia Classification and Metabolic Characteristics for Informing and Advancing Treatment.Cancers (Basel). 2024 Dec 11;16(24):4136. doi: 10.3390/cancers16244136. Cancers (Basel). 2024. PMID: 39766036 Free PMC article. Review.
-
Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia.Pharmacogenomics J. 2015 Jun;15(3):248-54. doi: 10.1038/tpj.2014.63. Epub 2014 Nov 4. Pharmacogenomics J. 2015. PMID: 25348617
-
Identifying risk factors for high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia.Cancer Manag Res. 2019 Jul 5;11:6265-6274. doi: 10.2147/CMAR.S207959. eCollection 2019. Cancer Manag Res. 2019. PMID: 31308758 Free PMC article.
-
Therapeutic effect and mechanism of Daikenchuto in a model of methotrexate-induced acute small intestinal mucositis.PLoS One. 2023 Mar 30;18(3):e0283626. doi: 10.1371/journal.pone.0283626. eCollection 2023. PLoS One. 2023. PMID: 36996098 Free PMC article.
-
The effect of Orem-based self-care education on improving self-care ability of patients undergoing chemotherapy: a randomized clinical trial.BMC Cancer. 2022 Jul 15;22(1):770. doi: 10.1186/s12885-022-09881-x. BMC Cancer. 2022. PMID: 35840918 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical